April 2024 - Thank you to everyone who shared their experiences in the iCMLf Hepatitis B Virus (HBV) and CML Screening and Management Survey.

Your contributions are essential to improving the understanding and management of Hepatitis B for people living with CML. This global collaboration - and the insights gained from your clinical practice - bring us one step closer to informing future recommendations and enhancing patient care.

Submissions are now open until April 24^th to help close regional data gaps.

Participation to date: A global snapshot

So far, we have received a total of 84 responses from physicians across 33 countries.

Participation was strongest in East Asia & Pacific and Europe & Central Asia, with 27 and 25 submissions respectively. Responses from Latin America & the Caribbean followed with 14, while Sub-Saharan Africa submitted 8, South Asia 6, and 2 responses each came from North America and the Middle East & North Africa regions.

In terms of country economic representation, the survey reached a broad spectrum. The majority of responses came from upper-middle income countries (40), followed by high-income countries (31). Lower-middle income countries contributed 10 responses, while low-income countries shared 3 submissions.

This diversity of backgrounds and practice settings will help to further our understanding of HBV management in CML across the globe.

Early insights: What we've learned so far

Across regions, one consistent practice emerged: Most physicians are screening for Hepatitis B reactivation prior to or during TKI therapy.

However, there is a striking absence of clear treatment guidelines, even in areas with a high prevalence of Hepatitis B. This highlights a global unmet need – and a real opportunity – to create robust, practical guidance for clinicians treating CML patients with a history of HBV.

Our goal moving forward will be to develop evidence-based recommendations, including adaptable best-practice strategies for low-resource environments. 

Survey extended – Help close the gap

New deadline: April 24^th

To ensure global representation, we’ve extended the survey deadline.
We are especially seeking more input from:

• Middle East & North Africa
• South Asia
• Sub-Saharan Africa

Submissions from all other regions are also welcome. Every voice counts in shaping this initiative.

Take part in the survey here

It takes just a few minutes to complete - and your insights could significantly influence global clinical practice. 

What’s next?

Thank you for your continued support of this important research project. We will keep you updated on the progress and final publication of the findings.

iCMLf HBV Working Group:
Chair, Dragana Milojkovic (UK),
Katia Pagnano (Brazil),
Qian Jiang (China),
Delphine Réa (France),
Hemant Malhotra (India),
Fausto Castagnetti (Italy), 
Giuseppe Saglio (Italy),
Salam Al Kindi (Oman), 
Mohamed Yassin (Qatar), 
Charles Chuah (Singapore), 
Jorge Cortes (USA)